The plasma protein therapeutics market was valued at USD 25.71 billion in 2021, and it is projected to expand to USD 48.06 billion by 2030 at a compound annual growth rate (CAGR) of 7.32% from 2023 to 2020.
.jpg "The Global Plasma Protein Therapeutic Market 2020-2030 (USD Billion)")
Major factors expected to drive the plasma protein therapeutic market growth in upcoming years are endorsement of the product across several manifestation, growing research & development activities as well as rising demand for advanced therapeutic alternative.
The global market of plasma protein therapeutic has been segmented by different product, application and geography. Further, product segment of the market is Immunoglobulin (IG), albumin, plasma-derived factor VIII and others. Immunoglobulin (IG) led the market in 2017 with major plasma protein therapeutic market share owing to the approval of biologics across several manifestation, easy administration as well as cost-effective treatment. Likewise, application segment of the market is sub-segmented into Idiopathic Thrombocytopenic Purpura (ITP), Primary Immunodeficiency Diseases (PID), Hemophilia and others.
Geographically, global plasma protein therapeutic market is led by North America and Europe, as large number of plasma for the plasma protein manufacture is collected in over 450 collection centers in the United States and Europe. Other key regions include Middle East & Africa (MEA), Asia Pacific and Latin America.
Some of the key players operating in the competitive edge of plasma protein therapeutic market include Octapharma AG, CSL Behring LLC, Grifols S.A., Shire Plc, Biotest AG, Bayer AG and Kedrion S.P.A. CSL Behring LLC dominated the global market in 2017, acquiring more than 20.0% of the overall market share.
Furthermore, market is expected to remain competitive with large number of players focusing over innovative drug development as well as expanding the network of plasma collection. In addition, Grifols S.A. acquired around 24 plasma donor centers in the United States, in August 2018 that was operated by Biotest AG. Moreover, organizations are targeting over collaborations for expanding their product portfolio as well as regional presence & organizing clinical trials in order to boost their market share.
Plasma Protein Therapeutic Market Scope
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2030 |
| Study Period | 2018-2030 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2030 | USD 48.06 billion |
| Growth Rate | CAGR of 7.32% during 2020-2030 |
| Segment Covered | Product, application, Regions |
| Regions Covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
| Key Players Profiled | Octapharma AG, CSL Behring LLC, Grifols S.A., Shire Plc, Biotest AG, Bayer AG and Kedrion S.P.A. CSL Behring LLC |
Key segments of the global plasma protein therapeutic market include:
- Product Segment of plasma protein therapeutic market
- Albumin
- Immunoglobulin
- Fibrinogen
- Segment of plasma protein therapeutic market
- Hemophilia
- Primary Immunodeficiency Disorder (PID)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Others
- Geographical Segmentation of plasma protein therapeutic market
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- Japan
- China
- Latin America
- Brazil
- Mexico
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- North America
Frequently Asked Questions (FAQ) :
The top companies that hold the market share in plasma protein therapeutic market are Octapharma AG, CSL Behring LLC, Grifols S.A., Shire Plc, Biotest AG, Bayer AG and Kedrion S.P.A. CSL Behring LLC & among others.
To get latest version of plasma protein therapeutic market report can be obtained on demand from the website.
The base year for the report is 2023 in plasma protein therapeutic market.